136 related articles for article (PubMed ID: 28981733)
41. Characteristics and Outcomes of Primary Central Nervous System Lymphoma: A Retrospective Study of 91 Cases in a Chinese Population.
Mao C; Chen F; Li Y; Jiang X; Liu S; Guo H; Huang L; Wei X; Liang Z; Li W; Tang K
World Neurosurg; 2019 Mar; 123():e15-e24. PubMed ID: 30326304
[TBL] [Abstract][Full Text] [Related]
42. Interim
Jo JC; Yoon DH; Kim S; Lee K; Kang EH; Park JS; Ryu JS; Huh J; Park CS; Kim JH; Lee SW; Suh C
Ann Hematol; 2017 Sep; 96(9):1509-1515. PubMed ID: 28725988
[No Abstract] [Full Text] [Related]
43. Long-term remission of primary central nervous system lymphoma by intensified methotrexate chemotherapy.
Watanabe T; Katayama Y; Yoshino A; Komine C; Yokoyama T; Fukushima T
J Neurooncol; 2003 May; 63(1):87-95. PubMed ID: 12814260
[TBL] [Abstract][Full Text] [Related]
44. Blood-brain barrier disruption and intra-arterial methotrexate-based therapy for newly diagnosed primary CNS lymphoma: a multi-institutional experience.
Angelov L; Doolittle ND; Kraemer DF; Siegal T; Barnett GH; Peereboom DM; Stevens G; McGregor J; Jahnke K; Lacy CA; Hedrick NA; Shalom E; Ference S; Bell S; Sorenson L; Tyson RM; Haluska M; Neuwelt EA
J Clin Oncol; 2009 Jul; 27(21):3503-9. PubMed ID: 19451444
[TBL] [Abstract][Full Text] [Related]
45. Reduced neurotoxicity with combined treatment of high-dose methotrexate, cyclophosphamide, doxorubicin, vincristine and prednisolone (M-CHOP) and deferred radiotherapy for primary central nervous system lymphoma.
Ichikawa T; Kurozumi K; Michiue H; Ishida J; Maeda Y; Kondo E; Kawasaki A; Date I
Clin Neurol Neurosurg; 2014 Dec; 127():106-11. PubMed ID: 25459253
[TBL] [Abstract][Full Text] [Related]
46. Monotherapy with methotrexate for primary central nervous lymphoma has single agent activity in the absence of radiotherapy: a single institution cohort.
Cobert J; Hochberg E; Woldenberg N; Hochberg F
J Neurooncol; 2010 Jul; 98(3):385-93. PubMed ID: 20020180
[TBL] [Abstract][Full Text] [Related]
47. Outcomes of older patients with primary central nervous system lymphoma treated in routine clinical practice in the UK: methotrexate dose intensity correlates with response and survival.
Martinez-Calle N; Poynton E; Alchawaf A; Kassam S; Horan M; Rafferty M; Kelsey P; Scott G; Culligan DJ; Buckley H; Lim YJ; Ngu L; McCulloch R; Rowntree C; Wright J; McKay P; Fourali S; Eyre TA; Smith J; Osborne W; Yallop D; Linton K; Fox CP; Cwynarski K
Br J Haematol; 2020 Aug; 190(3):394-404. PubMed ID: 32232989
[TBL] [Abstract][Full Text] [Related]
48. Role of rituximab in treatment of patients with primary central nervous system lymphoma: a retrospective analysis of the Czech lymphoma study group registry.
Mocikova H; Pytlik R; Sykorova A; Janikova A; Prochazka V; Vokurka S; Berkova A; Belada D; Campr V; Buresova L; Trneny M;
Leuk Lymphoma; 2016 Dec; 57(12):2777-2783. PubMed ID: 27087066
[TBL] [Abstract][Full Text] [Related]
49. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial.
Thiel E; Korfel A; Martus P; Kanz L; Griesinger F; Rauch M; Röth A; Hertenstein B; von Toll T; Hundsberger T; Mergenthaler HG; Leithäuser M; Birnbaum T; Fischer L; Jahnke K; Herrlinger U; Plasswilm L; Nägele T; Pietsch T; Bamberg M; Weller M
Lancet Oncol; 2010 Nov; 11(11):1036-47. PubMed ID: 20970380
[TBL] [Abstract][Full Text] [Related]
50. Proton magnetic resonance spectroscopy in immunocompetent patients with primary central nervous system lymphoma.
Raizer JJ; Koutcher JA; Abrey LE; Panageas KS; DeAngelis LM; Lis E; Xu S; Zakian KL
J Neurooncol; 2005 Jan; 71(2):173-80. PubMed ID: 15690135
[TBL] [Abstract][Full Text] [Related]
51. High-dose methotrexate combined with rituximab improves the survival rate of patients with primary central nervous system lymphoma.
Fu J; Ma X
J BUON; 2021; 26(2):366-372. PubMed ID: 34076981
[TBL] [Abstract][Full Text] [Related]
52. Prognostic impact of intraocular involvement in primary CNS lymphoma: experience from the G-PCNSL-SG1 trial.
Kreher S; Strehlow F; Martus P; Roth P; Hertenstein B; Röth A; Birnbaum T; Griesinger F; Rauch M; Kanz L; Thiel E; Weller M; Korfel A
Ann Hematol; 2015 Mar; 94(3):409-14. PubMed ID: 25217230
[TBL] [Abstract][Full Text] [Related]
53. Diagnostic delay and outcome in immunocompetent patients with primary central nervous system lymphoma in Spain: a multicentric study.
Velasco R; Mercadal S; Vidal N; Alañá M; Barceló MI; Ibáñez-Juliá MJ; Bobillo S; Caldú Agud R; García Molina E; Martínez P; Cacabelos P; Muntañola A; García-Catalán G; Sancho JM; Camro I; Lado T; Erro ME; Gómez-Vicente L; Salar A; Caballero AC; Solé-Rodríguez M; Gállego Pérez-Larraya J; Huertas N; Estela J; Barón M; Barbero-Bordallo N; Encuentra M; Dlouhy I; Bruna J; Graus F;
J Neurooncol; 2020 Jul; 148(3):545-554. PubMed ID: 32524392
[TBL] [Abstract][Full Text] [Related]
54. Stereotactic radiosurgery in combination with up-front high-dose methotrexate as a first-line treatment for newly diagnosed primary central nervous system lymphoma.
Hirono S; Iwadate Y; Higuchi Y; Serizawa T; Nagano O; Matsutani T; Saeki N
J Neurooncol; 2015 Jun; 123(2):237-44. PubMed ID: 25911295
[TBL] [Abstract][Full Text] [Related]
55. LMO2 and BCL6 are associated with improved survival in primary central nervous system lymphoma.
Lossos C; Bayraktar S; Weinzierl E; Younes SF; Hosein PJ; Tibshirani RJ; Sutton Posthumus J; DeAngelis LM; Raizer J; Schiff D; Abrey L; Natkunam Y; Lossos IS
Br J Haematol; 2014 Jun; 165(5):640-8. PubMed ID: 24571259
[TBL] [Abstract][Full Text] [Related]
56. First-line treatment and outcome of elderly patients with primary central nervous system lymphoma (PCNSL)--a systematic review and individual patient data meta-analysis.
Kasenda B; Ferreri AJ; Marturano E; Forst D; Bromberg J; Ghesquieres H; Ferlay C; Blay JY; Hoang-Xuan K; Pulczynski EJ; Fosså A; Okoshi Y; Chiba S; Fritsch K; Omuro A; O'Neill BP; Bairey O; Schandelmaier S; Gloy V; Bhatnagar N; Haug S; Rahner S; Batchelor TT; Illerhaus G; Briel M
Ann Oncol; 2015 Jul; 26(7):1305-13. PubMed ID: 25701456
[TBL] [Abstract][Full Text] [Related]
57. Primary central nervous system lymphoma in immunocompetent individuals: a single center experience.
Aki H; Uzunaslan D; Saygin C; Batur S; Tuzuner N; Kafadar A; Ongoren S; Oz B
Int J Clin Exp Pathol; 2013; 6(6):1068-75. PubMed ID: 23696924
[TBL] [Abstract][Full Text] [Related]
58. Immunohistochemistry for c-myc and bcl-2 overexpression improves risk stratification in primary central nervous system lymphoma.
Hatzl S; Posch F; Deutsch A; Beham-Schmid C; Stöger H; Greinix H; Pichler M; Neumeister P; Prochazka KT
Hematol Oncol; 2020 Aug; 38(3):277-283. PubMed ID: 32101329
[TBL] [Abstract][Full Text] [Related]
59. A single-center retrospective analysis of outcome measures and consolidation strategies for relapsed and refractory primary CNS lymphoma.
Bonm AV; Gibson AW; Holmberg LA; Mielcarek M; McGranahan T; Taylor LP; Graber JJ
J Neurooncol; 2021 Jan; 151(2):193-200. PubMed ID: 33398532
[TBL] [Abstract][Full Text] [Related]
60. Immunochemotherapy using rituximab (RTX) and high-dose methotrexate (HD-MTX): an evaluation of the addition of RTX to HD-MTX in recurrent primary central nervous system lymphoma (PCNSL).
Miyakita Y; Ohno M; Takahashi M; Muragaki Y; Katai H; Narita Y
Jpn J Clin Oncol; 2017 Oct; 47(10):919-924. PubMed ID: 28981729
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
